APVO — Aptevo Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $5.19m
- -$4.22m
- 20
- 45
- 50
- 30
Annual income statement for Aptevo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.31 | 12.3 | 3.11 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 33.9 | 33.7 | -5.43 | 28.9 | 24.6 |
| Operating Profit | -29.6 | -21.4 | 8.54 | -28.9 | -24.6 |
| Gain / Loss on Sale of Assets | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -30.9 | -29.4 | 7.01 | -18.6 | -24.1 |
| Net Income After Taxes | -30.9 | -29.4 | 7.01 | -18.6 | -24.1 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -17.8 | -28.5 | 8.03 | -17.4 | -24.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.8 | -28.5 | 8.03 | -17.4 | -24.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -276,693 | -204,230 | -192,492 | -75,315 | -64,664 |